The crux of HRS therapy still revolves around an attempt to rule out other causes (infections, glomerular disease, shock, and acute tubular necrosis) concomitant with volume expansion with albumin for 48 h followed by initiation of vasoconstrictors. The gene discussed is ALB; the disease is infection.